Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2018-01-04 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
第九届董事会第九次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 9th meeting of the 9th board of directors of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It extensively discusses the approval of a plan for issuing shares to purchase assets and raise supporting funds, including detailed terms of the asset purchase, pricing, issuance, lock-up periods, and related agreements. It also covers compliance with relevant Chinese securities laws and regulations, audit and evaluation reports, and the legal and procedural completeness of the transaction. The document is a formal board meeting resolution announcement related to a capital raising and asset acquisition transaction, with voting results and references to subsequent shareholder meeting approvals. It is not a full financial report, audit report, or earnings release, nor is it a simple announcement or proxy solicitation. The content fits best under Capital/Financing Update (CAP) as it details the company's financing activities and capital structure changes through share issuance and asset purchase.
2018-01-04 Chinese
董事会关于本次重组相关主体不存在依据《关于加强与上市公司重大资产重组相关股票异常交易监管的暂行规定》第十三条不得参与任何上市公司重大资产重组情形的说明
Regulatory Filings Classification · 95% confidence The document is a formal statement from the board of directors of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. regarding the compliance of parties involved in a major asset restructuring with regulatory provisions about stock trading and participation in asset restructurings. It references specific regulatory rules related to major asset restructuring and insider trading investigations but does not contain financial data, earnings, or detailed report content. The document is short (818 characters) and serves as a compliance explanation or announcement related to a restructuring event rather than the restructuring report itself. Therefore, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2018-01-04 Chinese
董事会关于发行股份购买资产并募集配套资金暨关联交易履行法定程序的完备性、合规性及提交的法律文件的有效性的说明
Capital/Financing Update Classification · 95% confidence The document is a detailed explanation from the board of directors regarding the legal and procedural compliance of a major asset restructuring transaction involving issuance of shares to purchase assets and raise supporting funds. It references specific regulatory frameworks such as the "Listing Company Major Asset Restructuring Management Measures" and the Shanghai Stock Exchange listing rules. The document outlines the steps taken, approvals obtained, and legal validity of submitted documents. It does not contain financial statements or earnings data but focuses on the procedural and legal compliance of a capital transaction. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is 2804 characters, which is substantive and not a mere announcement or certification. Therefore, the classification is CAP with high confidence.
2018-01-04 Chinese
东兴证券股份有限公司关于公司发行股份购买资产之独立财务顾问专业意见附表第3号——发行股份购买资产
Capital/Financing Update Classification · 95% confidence The document is a detailed independent financial advisor's professional opinion report related to a company's issuance of shares to purchase assets. It includes extensive due diligence, compliance with laws and regulations, asset valuation, transaction pricing fairness, and impact on the company. The document is lengthy (over 10,000 characters) and contains substantive financial and transaction analysis. It is not a simple announcement or certification but a comprehensive advisory report on a capital transaction involving issuance of shares to purchase assets. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document is not an Annual Report, Audit Report, or other categories. Therefore, the correct classification is CAP with high confidence.
2018-01-04 Chinese
审阅报告
Regulatory Filings
2018-01-04 Chinese
发行股份购买资产并募集配套资金暨关联交易报告书（草案）摘要
Capital/Financing Update Classification · 95% confidence The document is a detailed report titled "发行股份购买资产并募集配套资金暨关联交易报告书（草案）" which translates to "Report on Issuance of Shares to Purchase Assets and Raise Supporting Funds and Related Party Transactions (Draft)". It discusses a major asset restructuring involving issuance of shares to purchase 100% equity of Shanghai Aoyuan, fundraising through non-public issuance of shares, detailed transaction terms, pricing, lock-up arrangements, profit compensation agreements, risk disclosures, and regulatory approvals required from the China Securities Regulatory Commission (CSRC) and other bodies. The document includes extensive financial data, transaction details, risk factors, and legal compliance information related to a significant asset acquisition and capital raising. This type of document is characteristic of a Major Asset Restructuring Report or Major Asset Reorganization Report, which is a specific type of filing in Chinese capital markets for significant asset purchases and related capital raising. It is not an annual report, earnings release, or a simple announcement. It is a comprehensive transaction report with financial and legal details. Therefore, the most appropriate classification is "Capital/Financing Update" (CAP), as it covers issuance of shares, purchase of assets, and fundraising activities in detail. Confidence is high given the document length, content, and focus on financing and asset purchase.
2018-01-04 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.